USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 8451 – 8475 of 9023 Awards
Company: In Vitro Technologies, Inc. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: …BE USED (Q LIVER S9 AS A METABOLISM SYSTEM) AS MODEL COMPOUNDS WHICH SHOULD DISCRIMINATELY EFFECT THIS NEPHROTOXICITY BATTERY. IN VITRO TECHNOLOGIES CAPABLE OF PREDICTING TOXIC MECHANISMS WOULD MARKEDLY ACCELERATE THE PRODUCT DEVELOPMENT PROCESS IN THE PHARMACEUTICAL INDUSTRY… more
Company: LAKE PHARMACEUTICAL Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: N/A
Company: INTEGRATED LABORATORY SYSTEMS, INC. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 2
Abstract: … RESEARCH BY GOVERNMENT AGENCIES AND THE PRIVATE SECTOR. AWARDEE'S STATEMENT OF THE POTENTIAL COMMERCIAL APPLICATIONSOF THE RESEARCH: WHEN DEVELOPED, THE SINGLE CELL GEL ASSAY WILL BE USED BY PRIVATE INDUSTRY FOR THE TESTING OF GERM CELL ACTIVITY IN PHARMACEUTICALS AND CHEMICALS… more
Company: Interneuron Pharmaceuticals Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: … AGENTS, HAVE PRODUCED UNTOWARD CARDIOVASCULAR AND BEHAVIORAL EFFECTS AS A CONSEQUENCE OF THE DOSES REQUIRED TOSIGNIFICANTLY AFFECT FOOD INTAKE. LONG-TERM THERAPY WITH SOME OF THESE AGENTS HAS RESULTED IN THE DEVELOPMENT OF TOLERANCE, NECESSITATING THE NEED TO INCREASE DRUG… more
Company: INTERSYSTEMS, INC. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: THIS STUDY WILL DEVELOP AND PILOT TEST AN ASSESSMENT SCALE TO MEASURE DRUG ABUSE RISK AMONG AMERICAN WORKERS WITHIN EMPLOYEE ASSISTANCE PROGRAM (EAP) AND WORKPLACE SETTINGS. THE LONG-TERM OBJECTIVE OF THIS RESEARCH IS TO PRODUCE A RELIABLE, VALID, AND USEFUL MEASURE OF DRUG… more
Company: JACOBUS PHARMACEUTICAL COMPANY, INC. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: THE RESEARCH IS DESIGNED TO DEVELOP AN IMPROVED SYNTHETIC METHOD FOR THE PRODUCTION OF A NEW BIOEFFICIENT DERIVATIVE OF AN ORALLY ACTIVE IRON CHELATOR FOR THE TREATMENT OF IRON OVERLOAD. IN PHASE I HUMAN TRIALS, THE PARENT DRUG (GIVEN ORALLY IN CAPSULES) PRODUCED AN AMOUNT OF… more
Company: Kdc/isi Joint Venture Agency/Program/Year/Phase: USDA / SBIR / 1991 / 2
Abstract: … IN GRAINS FLOWING IN A CHUTEOR ON A CONVEYOR BELT, OR CONTAINED IN STORAGE OR TRANSPORT BINS. COMMERCIAL APPLICATIONS EXTEND TO OTHER FOOD PRODUCTSAND BYPRODUCTS, AND TO OTHER DIVERSE INDUSTRIES (E.G., FREEZE DRIED FOODS, CEREALS, SUGAR BEET PULP, PHARMACEUTICAL … more
Company: LANDEC CORP. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: THE MECHANICAL DEVELOPMENT OF A NOVEL, PULSED TRANSDERMAL THERAPEUTIC SYSTEM (TTS) IS DESCRIBED. THE PROTOTYPE TTS USES A MEMBRANE PREPARED FROM A UNIQUE POLYMER MATERIAL THAT IS PROPRIETARY TO LANDEC CORPORATION. THESE MEMBRANES HAVE A VERY LOW DRUG PERMEABILITY BELOW A… more
Company: Lasertherapeutics, Inc Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: PHOTODYNAMIC THERAPY, PDT, IS PRESENTLY UNDERGOING EXTENSIVE BASIC, PRECLINICAL AND CLINICAL TESTING FOR THE DIAGNOSIS AND TREATMENT OF CANCER. REGULATORY APPROVAL FOR THE FIRST PDT DRUG, PHOTOFRIN-II IS EXPECTED IN LATE 1991. CONCURRENT WITH THIS IS THE INTRODUCTION OF A NUMBER… more
Company: Lidak Pharmaceuticals Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: BEHENYL ALCOHOL (DOCOSANOL) IS A LONG CHAIN (C-22) SATURATED ALCOHOL WHICH HAS SIGNIFICANT ANTI-VIRAL PROPERTIES. INOCULATION OF ADULT MICE WITH FRIEND VIRUS, A MURINE RETROVIRUS, INDUCES LEUKEMIA, IMMUNOSUPPRESSION, AND ULTIMATELY DEATH; ADMINISTRATION OF BEHENYL ALCOHOL (TRADE-NAMED LIDAKOL) IN A… more
Company: Lidak Pharmaceuticals Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: THE LONG TERM OBJECTIVE IS TO ESTABLISH RELIABLE HUMAN TUMOR XENOGRAFT SYSTEMS WHICH WILL BE USED IN THE TREATMENT OF NON-HODGKIN'S LYMPHOMA AS WELL AS OTHER CANCERS. COMMERCIAL APPLICATIONS WHICH WOULD DERIVE FROM SUCH SYSTEMS INCLUDE: (I) IMPROVED SCREENING OF COMPOUNDS FOR ANTI-TUMOR ACTIVITIES;… more
Company: Lynntech, Inc. Agency/Program/Year/Phase: NSF / SBIR / 1991 / 1
Abstract: ELECTRONICALLY CONDUCTING ORGANIC POLYMERS ARE A NEW CLASS OF LOW-COST, LIGHTWEIGHT CONDUCTING MATERIALS THAT HAVE A LARGE NUMBER OF IMPORTANT PRACTICAL APPLICATIONS. THESE POLYMERS ARE OF PARTICULAR INTEREST IN THE AREA OF CONTROLLED DRUG RELEASE, SINCE THEY CAN BIND AND… more
Company: MARTEK BIOSCIENCE CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: … PRODUCING BETA-CAROTENE. WE HAVE IDENTIFIED A MICROALGAL SPECIES WHICH CAN BE GROWN UNDER CONVENTIONAL, CLEAN-ROOM, FERMENTATION CONDITIONS, AND PRODUCES A MIXTURE OF BETA-CAROTENE AND GAMMA-CAROTENE. THE GOAL OF THIS RESEARCH PROJECT IS TO PRODUCE A PHARMACEUTICAL… more
Company: Matrix Pharmaceutical Inc Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: MATRIX PHARMACEUTICAL, INC. IS FOCUSED ON DEVELOPMENT OF THE THERAPEUTIC IMPLANT (TI), A NOVEL INJECTABLE SUSTAINED-RELEASE DRUG PRODUCT. THE TI, A VISCOUS INJECTABLE GEL, IS COMPRISED OF A PROTEIN CARRIER MATRIX, VASOACTIVE TISSUE MODIFIER AND THERAPEUTIC AGENT. THE TI… more
Company: Media Group of CT. Agency/Program/Year/Phase: ED / SBIR / 1991 / 2
Abstract: AS PRODUCERS OF ONE OF THE U.S. DEPARTMENT OF EDUCATION'S EIGHT SUBSTANCE ABUSE PREVENTION VIDEOS DISTRIBUTED TO EVERYSCHOOL IN THE NATION, WE WILL COMBINE OUR EXPERTISE WITH THAT OF PREVENTION AND EVALUATION EXPERTS FROM YALE UNIVERSITY PSYCHOLOGY DEPARTMENT AND THE CONNECTICUT DEPARTMENT OF… more
Company: Micro-med, Inc Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: ERYTHROCYTE MEMBRANE FRAGILITY MAY BE ALTERED BY DISEASE, AGE, AND DRUGS AND PLAYS AN IMPORTANT ROLE IN THE SURVIVAL AND FUNCTION OF THE ERYTHROCYTE. THE ONLY COMMONLY USED TECHNIQUE FOR ASSESSING THIS PARAMETER, THE OSMOTIC FRAGILITY TEST, IS VERY TIME CONSUMING, GIVES AN… more
Company: Epoch Pharmaceuticals, Inc. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: IN THIS PHASE I STUDY WE WILL IMPROVE THE EFFICIENCY AND DEVELOP THE LINKING CHEMISTRY OF A NOVEL CLASS OF DNA CLEAVAGE REAGENTS. THESE AGENTS, WHICH UNDERGO THERMALLY TRIGGERED RADICAL FORMATION WILL BE MODIFIED WITH AN INTERCALATING GROUP IN ORDER TO INCREASE THE EFFICIENCY OF DNA CLEAVAGE. THE… more
Company: Epoch Pharmaceuticals, Inc. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: A SECRETABLE ALKALINE PHOSPHATASE (SPAP) REPORTER GENE WILL BE SUBSTITUTED FOR A PORTION OF THE ENV GENE IN AN HIV PROVIRAL DNA CLONE. EXPRESSION OF THE REPORTER GENE WILL BE REGULATED BY A COMPLETE COMPLEMENT OF VIRAL CIS AND TRANS ACTING CONTROL ELEMENTS, SUCH THAT THE LEVEL OF EXTRACELLULAR… more
Company: Epoch Pharmaceuticals, Inc. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: UNIQUELY MODIFIED ANTI-SENSE OLIGODEOXYNUCLEOTIDES (ODNS) TARGETED TO THE HEPATITIS B SURFACE ANTIGEN TRANSCRIPT WILL BE EVALUATED IN A DIFFERENTIATED HEPATOMA CELL LINE WHICH SUPPORTS THE CONSTITUTIVE PRODUCTION OF INFECTIOUS DANE PARTICLES. INHIBITION OF SURFACE ANTIGEN PRODUCTION WILL BE… more
Company: MOLECULAR DESIGN INTERNATIONAL, INC. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 2
Abstract: … REMISSIONS THAT AREEMOTIONALLY AND PHYSICALLY DEBILITATING. SEVERAL TREATMENTSARE AVAILABLE, BUT IN MANY CASES THESE ARE INADEQUATE. THIS APPLICATION IS BASED ON THE PREMISE THAT TOPICAL ADMINISTRATION OF PRODRUGS SHOULD RESULT IN HIGH CONCENTRATIONS OF THE ACTIVE DRUG AT THE… more
Company: Molecular Oncology Inc Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: …OLOGICALLY ACTIVE TIMP-2 AND 72 KD TYPE IV COLLAGENASE BY RECOMBINANT DNA TECHNOLOGY AND CHARACTERIZE THEIR BIOCHEMICAL AND BIOLOGICAL PROPERTIES. AVAILABILITY OF THESE PROTEINS WILL ALLOW US TO STUDY THEIR ROLE IN DISEASE AND TO DEVELOP ANTIBODIES AND SPECIFIC DRUGS TO BE USED… more
Company: Molecular Solvometrics, Inc. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: N/A
Company: Moravek Biochemicals, Inc. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 1
Abstract: THE GOAL OF THIS PROJECT IS TO MAINTAIN AND OPERATE A SPECIALIZED LABORATORY FOR THE SYNTHESIS OF SELECTED ANTI-CANCER AND ANTI-AIDS COMPOUNDS LABELED WITH CARBON-14, TRITIUM OR SULFUR-35. IN ADDITION, WE WILL DEVELOP THE RADIOSYNTHESIS OF SUCH DRUGS SELECTED BY NCI. THE LABEL… more
Company: Neurex Corp. Agency/Program/Year/Phase: HHS / SBIR / 1991 / 2
Abstract: OPIOID PEPTIDES AND DRUGS CAUSE MULTIPLE EFFECTS IN THE CENTRAL NERVOUS SYSTEM AND THROUGHOUT THE ENTIRE BODY. SEVERAL DISTINCT OPIOID RECEPTORS HAVE BEEN DESCRIBED BIOCHEMICALLY AND PHARMACOLOGICALLY, BUT THE GENES ENCODING THEM REMAIN UNKNOWN. THIS PROJECT WILL IDENTIFY AND… more
Displaying 8451 – 8475 of 9023 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.